- Home
- CREV vs BTAI Comparison
CREV vs BTAI Comparison
Compare CREV & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- BTAI
- Stock Information
- Founded
- CREV 2007
- BTAI 2017
- Country
- CREV Ireland
- BTAI United States
- Employees
- CREV N/A
- BTAI N/A
- Industry
- CREV
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- BTAI Health Care
- Exchange
- CREV Nasdaq
- BTAI Nasdaq
- Market Cap
- CREV 7.2M
- BTAI 7.2M
- IPO Year
- CREV N/A
- BTAI 2018
- Fundamental
- Price
- CREV $2.73
- BTAI $1.99
- Analyst Decision
- CREV Strong Buy
- BTAI Buy
- Analyst Count
- CREV 1
- BTAI 5
- Target Price
- CREV $39.00
- BTAI $42.60
- AVG Volume (30 Days)
- CREV 14.2K
- BTAI 1.2M
- Earning Date
- CREV 01-01-0001
- BTAI 03-27-2025
- Dividend Yield
- CREV N/A
- BTAI N/A
- EPS Growth
- CREV N/A
- BTAI N/A
- EPS
- CREV N/A
- BTAI N/A
- Revenue
- CREV $39,261,077.00
- BTAI $2,266,000.00
- Revenue This Year
- CREV $40.76
- BTAI $105.36
- Revenue Next Year
- CREV $86.18
- BTAI $46.93
- P/E Ratio
- CREV N/A
- BTAI N/A
- Revenue Growth
- CREV 41.52
- BTAI 64.20
- 52 Week Low
- CREV $2.00
- BTAI $1.72
- 52 Week High
- CREV $17.15
- BTAI $49.58
- Technical
- Relative Strength Index (RSI)
- CREV 39.84
- BTAI 39.93
- Support Level
- CREV $2.64
- BTAI $1.76
- Resistance Level
- CREV $3.31
- BTAI $2.11
- Average True Range (ATR)
- CREV 0.28
- BTAI 0.28
- MACD
- CREV 0.02
- BTAI 0.02
- Stochastic Oscillator
- CREV 11.11
- BTAI 16.98
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.